Minirin Melt (Desmopressin)

Desmopressin is a synthetic vasopressin analogue that selectively activates V2 receptors in the kidney collecting ducts. This activation raises intracellular cAMP, prompting aquaporin‑2 water channels to move to the cell surface, which enhances water reabsorption. In bleeding disorders, V2 stimulation releases stored factor VIII and von Willebrand factor from endothelial cells.

The appropriate dose of Minirin Melt is individualized by the prescribing clinician based on the patient’s age, weight, renal function, severity of the condition, and response to therapy. Dosage adjustments may be required for special populations, and the prescriber will provide specific instructions.

Safety data for desmopressin during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Healthcare providers should weigh potential benefits against risks and consider alternative therapies when treating pregnant or nursing individuals.

To request Minirin Melt, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with natural vasopressin, desmopressin has a longer half‑life and a higher selectivity for V2 receptors, resulting in a reduced risk of vasoconstriction‑related side effects. It is also available in a convenient sublingual melt form, which can improve adherence relative to injectable or nasal formulations.

Minirin Melt should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original blister pack, protect them from moisture and direct sunlight, and discard any tablets that are damaged or past their expiration date.

The tablet is placed under the tongue and allowed to melt completely without chewing or swallowing whole. This sublingual route enables rapid absorption into the bloodstream, bypassing the gastrointestinal tract and providing consistent bioavailability.

The most critical safety concerns are severe hyponatremia and water intoxication, which can lead to seizures, coma, or cerebral edema. Patients should be monitored for sudden changes in weight, confusion, headache, or nausea, and serum sodium levels should be checked regularly.

Minirin Melt is contraindicated in patients with known hypersensitivity to desmopressin, uncontrolled hyponatremia, or severe renal impairment. Caution is also advised for individuals with uncontrolled hypertension, heart failure, or those taking other antidiuretic medications.